Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®
NCT00258856
Completed
The study is designed to evaluate the persistence of bactericidal antibodies in subjects aged 7 to 15 years (not yet 16 years) who had been vaccinated five years previously in Study 603-02. In addition, the kinetics of the antibody response will be evaluated in a subset of participants who will receive a booster dose of Menactra® vaccine and children in the same age group not previously vaccinated with a meningococcal vaccine or had meningitis disease who will receive a dose of Menactra® vaccine... Read More
Gender:
ALL
Ages:
Between 7 years and 15 years
Trial Updated:
01/21/2014
Locations: Not set, Jonesboro, Arkansas +1 locations
Conditions: Meningitis, Meningococcal Infection
Register for Updates
Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants
NCT00806195
Completed
The primary objective of this phase 3b study is to evaluate the safety and tolerability of Novartis MenACWY conjugate vaccine when administered with routine infant vaccinations to healthy infants
Gender:
ALL
Ages:
Between 55 days and 89 days
Trial Updated:
05/13/2013
Locations: 55 Central Arkansas Pediatric Clinic Pediatric 2301 Springhill Road Suite 200, Benton, Arkansas +5 locations
Conditions: Meningitis, Meningococcal Infection
Register for Updates
Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine
NCT00373958
Completed
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the 13-valent pneumococcal vaccine (13vPnC) compare to the 7-valent pneumococcal vaccine (7vPnC) and to compare the immune response to concomitant vaccines administered with 13vPnC and 7vPnC.
Gender:
ALL
Ages:
Between 42 days and 98 days
Trial Updated:
01/17/2013
Locations: Not set, Fayetteville, Arkansas +2 locations
Conditions: Vaccines, Pneumococcal
Register for Updates
A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA)
NCT01163747
Completed
This randomized, parallel-group, open-label study will evaluate the effect of Actemra (tocilizumab) on vaccination in patients with active rheumatoid arthritis who have an inadequate response to methotrexate and who have had an inadequate clinical response or were intolerant to treatment with one or more anti-tumor necrosis factor (anti-TNF) therapies.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
11/12/2012
Locations: Not set, Jonesboro, Arkansas
Conditions: Rheumatoid Arthritis
Register for Updates
S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer
NCT00045617
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. Vaccines may make the body build an immune response to kill tumor cells. Combining chemotherapy and radiation therapy with vaccine therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy and radiation therapy with vaccine therapy in treating patients who hav... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2012
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas +1 locations
Conditions: Lung Cancer
Register for Updates
Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™
NCT00772928
Completed
This study is designed to evaluate in a controlled manner the effect of Prevnar® on the immune responses of Pentacel™ Primary Objective - Stage I: To compare the immune responses elicited by an infant series of Pentacel™ when given at different times from or concurrently with a Pneumococcal conjugate vaccine (Prevnar®). Primary Objective - Stage II: To compare the immune responses elicited by a 4th dose of Pentacel™ when given at different times from or concurrently with Prevnar®.
Gender:
ALL
Ages:
Between 42 days and 89 days
Trial Updated:
01/30/2012
Locations: Not set, Fayetteville, Arkansas +2 locations
Conditions: Diphtheria, Tetanus, Haemophilus Infection, Pertussis, Polio
Register for Updates
Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children
NCT00391391
Completed
Primary Objective: To evaluate for each influenza strain the non-inferiority of Investigational Fluzone vaccine to the standard Fluzone® vaccine in healthy subjects aged 6 to 35 months or 3 to 8 years. Secondary Objectives: * To describe the immunogenicity of of Investigational Fluzone vaccine to the standard Fluzone® vaccine in healthy subjects aged 6 to 35 months or 3 to 8 years. * To describe the safety of of Investigational Fluzone vaccine to the standard Fluzone® vaccine in healthy subje... Read More
Gender:
ALL
Ages:
Between 6 months and 8 years
Trial Updated:
11/21/2011
Locations: Not set, Harrisburg, Arkansas +2 locations
Conditions: Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Register for Updates
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
NCT00355121
Completed
The purpose of this study is to evaluate the immunogenicity and safety of the concomitant administration of Menactra® vaccine and DAPTACEL® vaccine. The main objectives are: Immunogenicity: To evaluate the antibody responses to both vaccines when Menactra vaccine is given concomitantly with DAPTACEL® compared to when either vaccine is given alone. Safety: To evaluate the rate of local and systemic reactions when DAPTACEL® and Menactra vaccines are administered concomitantly compared to when... Read More
Gender:
ALL
Ages:
Between 4 years and 7 years
Trial Updated:
08/22/2011
Locations: Not set, Little Rock, Arkansas
Conditions: Meningococcal Meningitis, Tetanus, Diphtheria, Pertussis, Poliomyelitis
Register for Updates